Nabi Biopharmaceuticals Appoints Vice President of Sales and Marketing in Europe and Country Manager, Nabi Biopharmaceuticals UK Limited

BRAY, Ireland, Sept. 8 /PRNewswire-FirstCall/ — Nabi Biopharmaceuticals announced today that Edwin Klumper, M.D., has been named vice president, sales and marketing, Europe, Nabi Biopharmaceuticals Europe Limited; and Chris Tovey has been named country manager, Nabi Biopharmaceuticals UK Limited. Dr. Klumper, a 15-year veteran in the pharmaceutical industry, has held a number of leadership positions at Amgen. Mr. Tovey, a 20-year veteran of GlaxoSmithKline (GSK), has a proven track record in successfully commercialising vaccines, anti-microbials and other therapeutics throughout Europe.

In this newly created position, Dr. Klumper, who will be based at the company’s European headquarters in Bray, Ireland, will build and lead Nabi Biopharmaceuticals’ European regional sales and marketing capabilities, formulate and execute its European business strategy and direct the marketing efforts for the launch of its products in Europe, including StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine), following approvals for such products.

Mr. Tovey, who will be based in London, will build and lead Nabi Biopharmaceuticals’ UK and Ireland commercial organisation, launch the company’s products in those markets, and lead all related sales, marketing and reimbursement initiatives. Mr. Tovey will also work with Dr. Klumper to lead the European launches for StaphVAX.

LeRoux Jooste, senior vice president, global sales and marketing, Nabi Biopharmaceuticals, stated, “Edwin and Chris are joining us at a critical and exciting time, as we look forward to launching StaphVAX, PhosLo(R) and HEBIG(TM) in Europe. Their appointments, and the competencies they bring to Nabi Biopharmaceuticals, are directly aligned with our global commercialisation plans. They will work together to build a world-class leadership team in Europe dedicated to building our franchises in nephrology and infection, and maximising our commercial success in our target European markets. We look forward to benefiting from their expertise and to augmenting our European team in a number of critical areas throughout 2005 and into 2006 under their leadership.”

Most recently, Dr. Klumper served as brand director for Aranesp(R), a licensed drug for the treatment of anaemia associated with chronic renal failure and chemotherapy-induced anaemia. During his tenure with Amgen, he refocused and aligned the company’s European marketing strategy and led a cross-functional team to build European key account management capabilities. These efforts resulted in the achievement of optimal revenues for Aranesp and a market leadership position for the product in Europe.

Dr. Klumper previously served as a business unit director at Amgen both in the Netherlands and the UK, where he was responsible for leading the nephrology unit. Prior to Amgen, Dr. Klumper worked at Asta Medica BV, in the Netherlands, where he served as business unit manager for the company’s oncology portfolio. During his time at Asta Medica BV, he in-licensed a portfolio of 10 generic oncology drugs and antibiotics, initiated and chaired an EU-based strategy force, and continuously achieved his annual profit targets. Dr. Klumper has also worked as a Research Fellow at VU Academic Hospital in the Netherlands, and is the author of a number of peer-reviewed articles. Dr. Klumper received his MBA from the Rotterdam School of Management in the Netherlands and a Ph.D. and M.D. from VU Academic Hospital in Amsterdam.

Mr. Tovey most recently served as director, commercial strategy distribution, Europe, for GSK. During his tenure, he was responsible for developing and leading key business initiatives within GSK, including market distribution and trade strategy. Prior to this position, Mr. Tovey served as director, vaccines therapy, for GSK, where he was responsible for leading commercial strategy in Europe for GSK’s broad vaccine portfolio, which included both marketed vaccines and products in development. He also served as GSK’s director, commercial development, UK; director, vaccines business unit, UK; and vaccines marketing manager, UK. He led pan European commercialisation efforts for a broad range of adult and paediatric vaccines, including Infanrix(R), Engerix(R)-B and Havrix(R), as well as leading sales efforts for antibiotic products for infectious diseases and Staphylococcal infections, including Augmentin(R), Zinnat(R), Timentin(R), and Bactroban(R). Mr. Tovey received a Bachelor of Science degree in Marine Biology from the University of Liverpool, UK.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are poised to capture large, commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, and kidney disease (nephrology), and opportunistically in nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and preclinical development. The company filed its Marketing Authorization Application (MAA) in Europe for its product candidate, StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate Vaccine], in December 2004. The application was accepted for review in January 2005. StaphVAX is currently in a confirmatory Phase III clinical trial in the United States. StaphVAX is designed to prevent the most dangerous and prevalent strains of S. aureus bacterial infections. S. aureus bacteria are a major cause of hospital-acquired infections and are becoming increasingly resistant to antibiotics. The company also filed MAA’s in Europe to market Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo(R) (calcium acetate), which is already marketed in the U.S. The company’s other products in development include Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], an antibody for prevention and treatment of S. aureus infections, NicVAX(TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website at http://www.nabi.com/.

This press release contains forward-looking statements that reflect the company’s current expectations regarding future events. Any such forward- looking statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may differ significantly from those in the forward-looking statements as a result of any number of factors, including, but not limited to, risks relating to the possibility that our confirmatory Phase III clinical trial for StaphVAX or our plans to commercialize StaphVAX in the European Union and United States may not be successful; the possibility that we may not realize the value of our acquisition of PhosLo; the company’s ability to raise additional capital on acceptable terms; the company’s dependence upon third parties to manufacture its products; the company’s ability to utilize the full capacity of its manufacturing facility; the impact on sales of Nabi-HB from patient treatment protocols and the number of liver transplants performed in HBV-positive patients; reliance on a small number of customers; the future sales growth prospects for the company’s biopharmaceutical products; and the company’s ability to obtain regulatory approval for its products in the United States or abroad or to successfully develop, manufacture and market its products. These factors are more fully discussed in the company’s Annual Report on Form 10-K for the fiscal year ended December 25, 2004 filed with the Securities and Exchange Commission.

Nabi Biopharmaceuticals

CONTACT: Constance C. Bienfait, VP, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800

Web site: http://www.nabi.com/